Markets:

Overview

News

Currencies

International

Treasuries

GH Research PLC - Ordinary Shares (NQ:GHRS)

15.69 +0.48 (+3.16%)

Streaming Delayed Price Updated: 3:03 PM EST, Jan 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GH Research PLC - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15% ↗

September 02, 2023

The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 15.0%, on average, in August and are now only up 5.3% YTD.

Via Talk Markets

Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More ↗

August 28, 2023

Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials

Via Benzinga

GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026 ↗

August 24, 2023

GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharma company developing novel mebufotenin (5-MeO-DMT) therapies for Treatment-Resistant Depression (TRD) and one of the highest trading...

Via Benzinga

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 23, 2023

From GH Research PLC

Via GlobeNewswire

GH Research: Q1 Earnings Insights ↗

May 11, 2023

Via Benzinga

Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports ↗

August 21, 2023

Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds

Via Benzinga

Topics Cannabis Economy

Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend ↗

August 20, 2023

The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in...

Via Talk Markets

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗

August 14, 2023

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published

Via Benzinga

So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index ↗

August 13, 2023

The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD.

Via Talk Markets

Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗

August 03, 2023

A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...

Via Benzinga

July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average ↗

July 30, 2023

All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July:

Via Talk Markets

Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial ↗

July 28, 2023

UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023:

Via Benzinga

Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD ↗

July 23, 2023

The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug...

Via Talk Markets

Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD ↗

July 14, 2023

Our Psychedelic Drug Stocks Index is up 12.3% MTD and is now up 25.1% YTD.

Via Talk Markets

Psychedelic Stocks Jumped 10% Last Week ↗

July 09, 2023

The FDA released a positive draft guidance for developing psychedelic treatments and the 6 largest stocks in the Psychedelic Drug Stocks Index responded accordingly

Via Talk Markets

Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues ↗

July 01, 2023

Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up...

Via Talk Markets

The 3 Best Psychedelic Stocks to Buy Now ↗

June 29, 2023

Psychedelic stocks promise to bring therapeutics to market that were taboo until recently and have huge upside.

Via InvestorPlace

Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue ↗

June 17, 2023

There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD.

Via Talk Markets

Major Psychedelic Compound-Based Research & Development Stocks: June Update ↗

June 10, 2023

Psychedelic Drug Stocks Index has been revamped with the removal of Cybin (CYBN) which has dropped below $100M in market capitalization leaving 6 constituents in the Index

Via Talk Markets

May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances ↗

June 01, 2023

Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May.

Via Talk Markets

Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More ↗

May 15, 2023

Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths...

Via Benzinga

Arlo Technologies, Array Technologies, AirSculpt Technologies And Other Big Stocks Moving Higher On Friday ↗

May 12, 2023

U.S. stocks traded slightly lower, with the Dow Jones dropping around 15 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer ↗

May 11, 2023

GH Research PLC (NASDAQ: GHRS), a Dublin-based clinical-stage biotech company reported financial results for the first quarter ended March 31, 2023.

Via Benzinga

GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

May 11, 2023

From GH Research PLC

Via GlobeNewswire

April Psychedelic Drug Stocks Recap: The Ups And Downs ↗

April 30, 2023

Via Talk Markets

Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today ↗

April 21, 2023

Via Benzinga

Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today ↗

April 20, 2023

Via Benzinga

Cybin, Mind Medicine Among Top Psychedelic Movers Of Today ↗

April 19, 2023

Via Benzinga

Psychedelic Stock Gainers And Losers From April 18, 2023 ↗

April 18, 2023

Via Benzinga

Psychedelic Stock Gainers And Losers From April 17, 2023 ↗

April 17, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.